HIMS · Investment summary · as of 4 August 2026
Priced slightly ahead of what the business has demonstrated
Business type: Inflection · scaling but economically observable
The business does not meet the quality standard for its economic type.
At $30.82, HIMS requires a 36% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 33%.
The conditions that would settle the disagreement are dated to December 2027.
The value rests on an exit multiple of 8.8x, a terminal operating margin of 12% and a 11.5% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: The compounded-GLP-1 route is closed to HIMS by action rather than by argument, and the branded-resale and peptide successors do not replace it.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | TTM revenue $2,369.7m (Q2'25 544.8 + Q3'25 599.0 + Q4'25 617.8 + Q1'26 608.1, all filed 10-Q/10-K). TTM EBIT -$30.6m (26.7 + 11.8 + 9.2 - 78.3). TTM gross profit $1,699.5m. |
| What do we forecast? | Revenue growth of 33% demonstrated; a terminal operating margin of 12%; an exit multiple of 8.8x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is -9.1 percentage points. |
| What is it worth? | Twelve-month target $37.74, +22% from the struck price. Scenario-weighted expected return net of costs +22.5%. |
| Why now? | The first dated test of the thesis falls on 31 December 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 30 June 2027 | TTM operating margin change, pp | Neither leg of the condition opposite is met at this date | TTM EBIT margin minus prior-TTM EBIT margin turns POSITIVE |
| 31 December 2026 | United States Revenue, YoY %, as disaggregated in the 10-Q | Neither leg of the condition opposite is met at this date | Filed United States Revenue returns to positive YoY growth for two consecutive quarters |
| tested every quarter from Q3 FY2026 | Us-gaap:MarketingExpense / revenue, and revenue YoY | Marketing expense falls at or above 32% of revenue for two consecutive quarters WHILE total revenue grows >= 20% YoY | Marketing expense falls below 32% of revenue for two consecutive quarters WHILE total revenue grows >= 20% YoY |
| 31 December 2027 | DOJ referral closed with no action AND SEC investigation closed with… | Neither leg of the condition opposite is met at this date | The enforcement overhang clears without action |
The compounded-GLP-1 route is closed to HIMS by action rather than by argument, and the branded-resale and peptide successors do not replace it. NAMED CAUSE, any one of: (a) the HHS General Counsel's February 2026 referral of HIMS to the DOJ produces an FDCA/Title-18 action; (b) the FDA executes the February 2026 statement - which names HIMS directly - restricting GLP-1 active pharmaceutical ingredients intended for non-FDA-approved compounded drugs mass-marketed as alternatives to approved drugs; (c) Novo Nordisk refiles the '343 patent suit (filed 9 February 2026 in D. Del., voluntarily dismissed WITHOUT PREJUDICE 9 March 2026, patent runs to 5 December 2031) and obtains the permanent injunction it requested; (d) the FDA finalises the Demonstrable Difficulties for Compounding List with semaglutide/tirzepatide on it, as the branded manufacturers have requested.
Estimated probability 30%, against the 14% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
Trim or exit when forward expected return to the rolling 12-month target falls to or below zero net of costs. On approach to the $37.74 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | The compounded-GLP-1 route is closed to HIMS by action rather than by argument, and the branded-resale and peptide successors do not replace it. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -9.1 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: the compounded-GLP-1 route is closed to HIMS by action rather than by argument, and the branded-resale and peptide successors do not replace it. The next evidence that should change the portfolio decision is the test dated 31 December 2026, or a daily close below $23.12, which forces an immediate review.